Indianapolis-based Corteva, Inc. (CTVA) supplies products to the agricultural input industry that protect crops against weeds, insects, pests, and diseases as well as enhance crop health. It operates through the Seed and Crop Protection segments. With a market cap of $48.4 billion, Corteva’s operations span the Americas, the Indo-Pacific, Europe, the Middle East, and Africa.

Corteva has significantly outperformed the broader market over the past year. CTVA stock has soared 24.5% on a YTD basis and 37.6% over the past year, outpacing the S&P 500 Index’s ($SPX) 8.6% gains in 2025 and 20.1% surge over the past 52 weeks.

Zooming in further, CTVA has also outperformed the First Trust Indxx Global Agriculture ETF’s (FTAG) 12.8% gains in 2025 and 11% returns over the past 52-week period.

Despite delivering better-than-expected results, Corteva’s stock prices observed a marginal dip in the trading session following the release of its Q2 results on Aug. 6. During the first half of the year, the company observed a solid growth in seed sales as well as crop protection revenues. Driven by increased corn area in North America, its seed revenues increased by 2%. Meanwhile, driven by demand for new products and biologicals, Corteva’s crop protection revenues increased by 3%. In Q2, its overall topline grew 5.6% year-over-year to $6.5 billion, beating Street estimates. Further, its adjusted EPS soared by 20.2% to $2.20, surpassing the consensus estimates by 16.4%.

However, the company’s topline growth has been completely driven by volume gains, and it has been facing pricing pressure. In H1, Corteva’s crop projection segment observed a 2% decline in product prices due to market dynamics in Latin America. Moreover, Corteva expects full-year crop protection revenues to remain mostly flat due to expected price dips in the coming quarters.

For the full fiscal 2025, ending in December, analysts expect CTVA to deliver an adjusted EPS of $3.13, up 21.8% year-over-year. The company has a mixed earnings surprise history. While it surpassed the Street’s bottom-line estimates twice over the past four quarters, it missed the projections on two other occasions.

The stock has a consensus “Strong Buy” overall. Of the 21 analysts covering the stock, opinions include 14 “Strong Buys,” two “Moderate Buys,” and five “Holds.”

This configuration has remained stable over the past three months.

On Aug. 8, Keybanc analyst Aleksey Yefremov reiterated an “Overweight” rating on CTVA and raised the price target from $84 to $85.

CTVA’s mean price target of $80.55 represents a premium of 13.6% to current price levels. Meanwhile, the street-high target of $92 suggests a notable upside potential of 29.7%.